Rigel stock sinks but analysts back AstraZeneca pact
Rigel stock sinks but analysts back AstraZeneca pact
Shares in Rigel Pharmaceutical shares have taken a dive after the US firm licensed its late-stage rheumatoid arthritis fostamatinib to AstraZeneca but analysts believe the market has acted far too harshly. After announcing the deal with the
Source: c.moreover.com
